Research Analysts Issue Forecasts for DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Investment analysts at HC Wainwright increased their FY2025 EPS estimates for shares of Bright Minds Biosciences in a research report issued on Tuesday, August 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.86) per share for the year, up from their prior estimate of ($2.12). HC Wainwright currently has a “Buy” rating and a $85.00 price target on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q2 2026 earnings at ($1.29) EPS, Q4 2026 earnings at ($1.83) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($5.87) EPS and FY2028 earnings at ($5.95) EPS.

A number of other analysts have also weighed in on the stock. Wall Street Zen lowered shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Cowen assumed coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They set a “buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bright Minds Biosciences in a report on Wednesday, July 2nd. TD Cowen assumed coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They set a “buy” rating on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $80.00 target price on shares of Bright Minds Biosciences in a report on Wednesday, May 21st. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $83.25.

Bright Minds Biosciences Trading Up 0.9%

Bright Minds Biosciences stock opened at $43.02 on Thursday. The firm’s 50 day simple moving average is $31.09 and its 200 day simple moving average is $32.67. The firm has a market capitalization of $302.86 million, a PE ratio of -46.26 and a beta of -6.07. Bright Minds Biosciences has a 1-year low of $0.94 and a 1-year high of $79.02.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its earnings results on Thursday, August 14th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.06.

Hedge Funds Weigh In On Bright Minds Biosciences

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Bright Minds Biosciences in the 2nd quarter worth $66,000. Sio Capital Management LLC increased its holdings in shares of Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company’s stock worth $13,377,000 after buying an additional 4,776 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Bright Minds Biosciences during the 2nd quarter valued at $107,000. JPMorgan Chase & Co. grew its holdings in shares of Bright Minds Biosciences by 624.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after purchasing an additional 1,873 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Bright Minds Biosciences during the 2nd quarter valued at $28,000. Institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.